Background: Many patients with rheumatoid arthritis (RA) achieve disease remission with modern treatment strategies. However, having achieved this state, there are no tests that predict when withdrawal of therapy will result in drug-free remission rather than flare. We aimed to identify predictors of drug-free remission in RA.
Methods: The Biomarkers of Remission in Rheumatoid Arthritis (BioRRA) Study was a unique, prospective, interventional cohort study of complete and abrupt cessation of conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs). Patients with RA of at least 12 months duration and in clinical and ultrasound remission discontinued DMARDs and were monitored for six months. The primary outcome was time-to-flare, defined as disease activity score in 28 joints with C-reactive protein (DAS28-CRP) ≥ 2.4. Baseline clinical and ultrasound measures, circulating inflammatory biomarkers, and peripheral CD4 T cell gene expression were assessed for their ability to predict time-to-flare and flare/remission status by Cox regression and receiver-operating characteristic (ROC) analysis respectively.
Results: 23/44 (52%) eligible patients experienced an arthritis flare after a median (IQR) of 48 (31.5-86.5) days following DMARD cessation. A composite score incorporating five baseline variables (three transcripts [FAM102B, ENSG00000228010, ENSG00000227070], one cytokine [interleukin-27], one clinical [Boolean remission]) differentiated future flare from drug-free remission with an area under the ROC curve of 0.96 (95% CI 0.91-1.00), sensitivity 0.91 (0.78-1.00) and specificity 0.95 (0.84-1.00).
Conclusion: We provide proof-of-concept evidence for predictors of drug-free remission in RA. If validated, these biomarkers could help to personalize immunosuppressant withdrawal: a therapy paradigm shift with ensuing patient and economic benefits.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6891251 | PMC |
| http://dx.doi.org/10.1016/j.jaut.2019.06.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Five-year follow-up of idiopathic granulomatous mastitis.
Ir J Med Sci
December 2024
Rheumatology Department, Gülhane Training and Research Hospital, University of Health Sciences Turkey, Ankara, Turkey.
Background: Idiopathic granulomatous mastitis (IGM) is a benign and rare chronic inflammatory disease of the breast. Although there are various treatment modalities, an ideal treatment algorithm has not been defined.
Aims: We designed this study to evaluate the clinical status, duration of remission, remission rates, and treatment algorithm in patients with IGM during a 5-year follow-up period after immunosuppressive therapy.
CAR-based cell therapies for systemic lupus erythematosus.
Chin Med J (Engl)
December 2024
Department of Rheumatology, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai 200127, China.
The remarkable efficacy of chimeric antigen receptor (CAR) T cell therapy in hematological malignancies has provided a solid basis for the therapeutic concept, wherein specific pathogenic cell populations can be eradicated by means of targeted recognition. During the past few years, CAR-based cell therapies have been extensively investigated in preclinical and clinical research across various non-tumor diseases, with particular emphasis in the treatment of autoimmune diseases (ADs), yielding significant advancements. The recent deployment of CD19-directed CAR T cells has induced long-lasting, drug-free remission in patients with systemic lupus erythematosus (SLE) and other systemic AD, alongside a more profound immune reconstruction of B cell repertoire compared with conventional immunosuppressive agents and B cell-targeting biologics.
View Article and Find Full Text PDFNeutrophil/lymphocyte ratio is increased in the acute phase of schizophrenia and regardless the use and types of antipsychotic drugs.
BMC Psychiatry
December 2024
Affiliated Xiaoshan Hospital, Hangzhou Normal University, Quanfeng Zhu, 728 Yucai North Road, Hangzhou, 311201, China.
Article Synopsis
- Patients with schizophrenia experience heightened inflammation during acute episodes, and the neutrophil/lymphocyte ratio (NLR) could serve as a potential biomarker for these exacerbations.
- A study involving 651 participants (including both healthy controls and various patient groups) analyzed inflammatory indices and found that NLR was significantly higher in drug-free and medicated patients during acute phases compared to healthy individuals.
- While NLR correlated with disease duration and mood stabilizer use, the platelet/lymphocyte ratio (PLR) and monocyte/lymphocyte ratio (MLR) showed no significant differences among the patient groups or with healthy controls.
Sustained Drug-Free Remission in Giant Cell Arteritis.
Rheumatology (Oxford)
November 2024
Department of Rheumatology. Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Objetive: To evaluate the frequency and timing of sustained drug-free remission (SDFR) in patients with giant cell arteritis (GCA) and to identify potential predictive factors of this outcome.
Methods: Retrospective review of all patients included in the large Spanish multicentre registry for GCA (ARTESER) with at least two years of follow-up. SDFR was defined as the absence of typical signs, symptoms, or other features of active GCA for ≥12 months after discontinuation of treatment.
Is rheumatoid arthritis always preceded by a symptomatic at-risk phase of arthralgia?
RMD Open
November 2024
Department of Rheumatology, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands
Article Synopsis
- The study examined whether the belief that all individuals with rheumatoid arthritis (RA) go through a 'pre-RA' phase of symptoms (arthralgia) is true by analyzing new RA patients over a decade.
- It included a cohort of 699 individuals diagnosed with RA, comparing those who had warning symptoms before diagnosis against those who did not, using advanced statistical methods.
- Findings revealed only about 55% of the patients experienced this 'pre-RA' stage, and those who did were generally younger and more likely to have specific antibodies, but they struggled more with long-term remission compared to those who did not have previous symptoms.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!